DC4U was recently awarded a NanoNextNL project aiming to create glycan-antigen based technologies, which can be applied to develop novel nanomedicines. In this project, “Nanoparticles Targeting Dendritic Cells for Anti-Tumor Vaccines”, we cooperate with VU Medical Centre, Leiden University Medical Centre, U-Protein Express and Podiceps.
The project focuses on developing multivalent glyco-peptide conjugates and glycoliposome formulations using defined tumor antigens that have shown clinical responses. These nano glycan-antigen constructs will significantly enhance tumor antigen specific immune responses by targeting of dendritic cells.
NanoNextNL is a consortium of more than one hundred companies, universities, knowledge institutes and university medical centres, which is aimed at research into micro and nanotechnology. The total sum involved for NanoNextNL is 250 million euros, half of which is contributed by the collaborations and the other half by the Government of the Netherlands.